Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dexmedetomidine and Midazolam for Pediatric MRI Premedication
NCT04356638Phase 3Unknown
- Sponsor
- King Faisal Specialist Hospital and Research Centre
- Start
- Oct 2021
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of dexmedetomidine and midazolam in anxiety disorder (4 arms), sponsored by King Faisal Specialist Hospital and Research Centre. Primary endpoints: Anxiety Level at 30 months, Hemodynamic stability at 30 months and 2 more. Status: unknown.
02
Drugs
dexmedetomidinemidazolam
03
Conditions
anxiety disorder
Beyond the preview
Go deeper on NCT04356638.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04356638.